CasLoc logo
All Cases PTAB Litigations UPC Oppositions

Forest Laboratories LLC v. InvaGen Pharmaceuticals Inc.

1:15-cv-01078

Overview

Case Number 1:15-cv-01078
Filing Date 2015-11-23
Status Terminated
Termination Date 2017-10-24
Court District Court, D. Delaware (ded)
Nature of Suit 830 Patent
Jurisdiction Type Federal Question
Cause of Action 35:271 Patent Infringement
Jury Demand None

Parties

Defendant

InvaGen Pharmaceuticals Inc. Operating Company

Represented By

0 Attorneys Listed
No attorneys available

Merck KGaA Operating Company

Represented By

2 Attorneys Listed

Maryellen Noreika

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Plaintiff

Merck Patent Gesellschaft mit beschrankter Haftung NPE (University / Research)

Represented By

2 Attorneys Listed

Maryellen Noreika

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Forest Laboratories LLC Operating Company

Represented By

2 Attorneys Listed

Maryellen Noreika

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Forest Laboratories Holdings Ltd. NPE (Patent Assertion Entity)

Represented By

2 Attorneys Listed

Maryellen Noreika

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Jack B. Blumenfeld

Morris, Nichols, Arsht & Tunnell LLP

Tel: +1 (302) 658-9200

1201 North Market Street, P.O. Box 1347

Court & Judges

Court

District Court, D. Delaware (ded)

Global Patent Family Cross-Litigation Radar

CasLoc 360Β° Radar 17 Family Members

Multi-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions

πŸ‡ΊπŸ‡Έ
U.S. District Courts Counterparts in force
πŸ›οΈ
USPTO PTAB Trials 1 proceeding
πŸ‡ͺπŸ‡Ί
Unified Patent Court (UPC) Counterparts in force
πŸ‡©πŸ‡ͺ
European Patent Office (EPO) Counterparts in force
Worldwide Family Members (17): πŸ‡ͺπŸ‡Ί Europe πŸ‡ΊπŸ‡Έ US 🌐 PCT
Parallel Proceedings Across Jurisdictions (1 found):
PTAB: 1
USPTO PTAB Trial 2018-01-05
IPR2018-00423

Argentum Pharmaceuticals LLC et al. v. Merck Patentgesellschaft Mit Beschrankter Haftung et al.

Asserted Patent
Status: Institution Denied
Stay ahead of cross-border rulings. Subscribe for free automated docket alerts across U.S. Courts, PTAB, UPC, and EPO.

Patents Involved

4 Patents

There are 4 patents involved in this case.

Patent Asset Filing & Issue Date Expiration & Term Status External Links
US7834020
Polymorphic forms of 1-β€²4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Filed: 2008-04-28
Issued: 2010-11-16
Active (1.4 yrs remaining)
Expires: 2028-04-28
US8193195
Polymorphic forms of 1-'4-(5-cyanoindol-3-yl) butyl-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Filed: 2010-11-12
Issued: 2012-06-05
Active (4.0 yrs remaining)
Expires: 2030-11-12
US8236804
Polymorphic forms of 1-β€²4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
Filed: 2011-05-04
Issued: 2012-08-07
Active (4.5 yrs remaining)
Expires: 2031-05-04
US8673921
Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl) piperazine hydrochloride
Filed: 2013-09-19
Issued: 2014-03-18
Active (6.8 yrs remaining)
Expires: 2033-09-19

Patent Enforceability & Injunction Risk Assessment

Statutory Analysis
Injunction Viability (35 U.S.C. Β§ 283) Active Threat

Active Threat β€” Patent is within enforceable statutory term. Patentee retains legal standing to seek permanent injunctive relief and exclusion orders.

Terminal Disclaimer & Cellect Risk Low Risk

Standard Statutory Term β€” No obviousness-type double patenting truncation noted.

Damages Lookback Horizon 6-Yr Max Lookback

Under 35 U.S.C. Β§ 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).

Docket Entries

(15 total)
Pleading / Complaint

COMPLAINT filed against InvaGen Pharmaceuticals Inc. - Magistrate Consent Notice to Pltf. ( Filing fee $ 400, receipt number 311-1832161.) - filed by Forest Laboratories LLC, Forest Laboratories Holdings Ltd., Merck KGaA, Merck Patent Gesellschaft mit beschrankter Haftung. (Attachments: # 1 Exhibit A - D, # 2 Civil Cover Sheet)(dmp, ) (Entered: 11/24/2015)

Entry #1 • 2015-11-23
1

Notice, Consent and Referral forms re: U.S. Magistrate Judge jurisdiction. (dmp, ) (Entered: 11/24/2015)

Entry #2 • 2015-11-23
1

Supplemental information for patent cases involving an Abbreviated New Drug Application (ANDA) - Date Patentee(s) Received Notice: 10/20/2015. Date of Expiration of Patent: 06/05/2022.Thirty Month Stay Deadline: 7/21/2018. (dmp, ) (Entered: 11/24/2015)

Entry #3 • 2015-11-23
1

Report to the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 7,834,020; 8,193,195; 8,236,804; 8,673,921;. (dmp, ) (Entered: 11/24/2015)

Entry #4 • 2015-11-23
1

Disclosure Statement pursuant to Rule 7.1: identifying Corporate Parent FL Holding CV, Other Affiliate FLI International LLC for Forest Laboratories Holdings Ltd.; Corporate Parent Tango U.S. Holdings Inc., Other Affiliate FLI International LLC, Other Affiliate Allergan plc (f/k/a Actavis plc) for Forest Laboratories LLC filed by Forest Laboratories Holdings Ltd., Forest Laboratories LLC. (dmp, ) (Entered: 11/24/2015)

Entry #5 • 2015-11-23
1

Track Case Updates

Automated email notifications for new filings & decisions

Identifier: •

Free service • 1-click unsubscribe anytime • Powered by CasLoc